BostonGene to Present Approach for Patient Stratification and Selection of IO Clinical Trials Using Molecular and Immune Profiling at the 11th Annual Immuno-Oncology Summit

On August 3, 2023 BostonGene reported that it will participate in and present at the 11th Annual Immuno-Oncology Summit, the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology, which is being held August 7 – 9, 2023 in Boston, MA (Press release, BostonGene, AUG 3, 2023, View Source [SID1234633799]). BostonGene will also exhibit at the conference, booth #20.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BostonGene session details are below:

Deciphering mechanisms of tumor immune escape using AI-driven analytics for patient stratification in clinical trials

Track: AI in Cancer Immunotherapy
Monday, August 7, 2023 | 11:55 AM ET
Speaker: Michael Goldberg, PhD, Director, Immunology and Immunoprofiling, R&D, BostonGene
Multiple molecular and cellular factors, such as TMB, immune infiltration, and active immunosuppression in the tumor microenvironment (TME), can influence poor patient responses to immunotherapy and IO clinical trial failure. Although the involvement of these factors is known to impact patient responses, they are often not considered in IO clinical trial enrollment and therapeutic decision-making. In this session, BostonGene will discuss how comprehensive profiling of a patient’s disease for therapy selection and stratification for IO clinical trials improves outcomes using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with best-in-class analytics.

To learn more or to schedule a meeting with BostonGene during the event, please contact Maria Proia at [email protected].